Shenzhen Yangli Pharmaceutical Technology Co. Ltd. has patented poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer, ischemia and neurodegeneration.
Adlai Nortye Biopharma Co. Ltd. has divulged molecular glue degraders acting as cyclin-dependent kinase 12 (CDK12)/cyclin K degradation inducers reported to be useful for the treatment of cancer, viral infections, autoimmune disease and inflammatory disorders.
Onquality Pharmaceuticals China Ltd. has described cyclin-dependent kinase 4 (CDK4) and/or cyclin-dependent kinase 6 (CDK6) inhibitors reported to be useful for the treatment of cancer therapy-associated disorders.
Jiangsu Vcare Pharmatech Co. Ltd. has disclosed tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer.
Researchers from the Chinese Academy of Sciences evaluated the highly potent and selective inhibitor of the second bromodomain (BD2) of the bromodomain and extra-terminal (BET) family of proteins, ABBV-744, with the aim of assessing its preclinical efficacy and exploring the pathways by which the compound regulates microglia-mediated neuroinflammation.
CSPC Pharmaceutical Group Ltd. has received clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials in China with SYS-6016, the company’s mRNA respiratory syncytial virus (RSV) vaccine.
One of the most common causes of adverse neurological disabilities in newborns is neonatal hypoxic-ischemic encephalopathy. Therapeutic hypothermia (TH) is the standard therapy, but it is not efficient in all cases. Cannabinoids have raised interest as therapeutics as they are neuroprotective.
Satellos Bioscience Inc. has submitted a clinical research proposal to a Human Research Ethics Committee (HREC) in Australia seeking regulatory authorization under the Therapeutic Goods Administration (TGA)’s clinical trial notification scheme to conduct a first-in-human phase I trial of SAT-3247.
Abeona Therapeutics Inc. and Beacon Therapeutics Ltd. have signed an agreement for evaluation by Beacon of Abeona’s patented AAV204 capsid for the development and commercialization of potential gene therapies for select ophthalmology indications.
RSS
